Biomarin Pharmaceutical (FRA:BM8) Change In Receivables : €-50 Mil (TTM As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Change In Receivables?

Biomarin Pharmaceutical's change in receivables for the quarter that ended in Mar. 2024 was €-3 Mil. It means Biomarin Pharmaceutical's Accounts Receivable increased by €3 Mil from Dec. 2023 to Mar. 2024 .

Biomarin Pharmaceutical's change in receivables for the fiscal year that ended in Dec. 2023 was €-175 Mil. It means Biomarin Pharmaceutical's Accounts Receivable increased by €175 Mil from Dec. 2022 to Dec. 2023 .

Biomarin Pharmaceutical's Accounts Receivable for the quarter that ended in Mar. 2024 was €586 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biomarin Pharmaceutical's Days Sales Outstanding for the three months ended in Mar. 2024 was 89.61.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biomarin Pharmaceutical's liquidation value for the three months ended in Mar. 2024 was €271 Mil.

Biomarin Pharmaceutical Change In Receivables Historical Data

The historical data trend for Biomarin Pharmaceutical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Change In Receivables Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-34.07

-48.53

58.03

-77.44

-174.63

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-129.64	-6.49	13.02	-53.64	-3.12

Biomarin Pharmaceutical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-50 Mil.

Biomarin Pharmaceutical (FRA:BM8) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biomarin Pharmaceutical's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	586.19	/	596.926	*	91
=	89.61

2. In Ben Graham's calculation of liquidation value, Biomarin Pharmaceutical's accounts receivable are only considered to be worth 75% of book value:

Biomarin Pharmaceutical's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	962.854	-	1654.948	+	0.75 * 586.19	+	0.5 * 1046.943
=	271

Biomarin Pharmaceutical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (FRA:BM8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines